927 results on '"Bjurlin, Marc A."'
Search Results
2. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes
3. Urologists’ Perceptions and Practices Related to Patient Smoking and Cessation: A National Assessment From the 2021 American Urological Association Census
4. Bladder Cancer Carcinogens: Opportunities for Risk Reduction
5. Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot
6. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
7. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.
8. Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications
9. Urinary Biomarkers: Current Status and Future Opportunities
10. Can genitourinary cancer survivors understand quality of life (QoL) questionnaires? Assessing the readability of commonly used urologic oncology QoL instruments
11. PD30-09 RESPONSE TO PRIMARY CHEMOABLATION WITH UGN-102 IN PATIENTS WITH NEW OR RECURRENT LG IR NMIBC: POST-HOC ANALYSIS OF THE ATLAS TRIAL
12. MP12-17 UNDERSTANDING PATIENT DECISION-MAKING FOR CLINICAL T1 RENAL MASSES
13. PD41-12 EXPLORING RECURRENCE AFTER INITIAL RESPONSE TO UGN-101 INDUCTION IN EXPANDED SETTINGS
14. PD41-11 LONGITUDINAL FOLLOW UP OF MULTICENTER STUDY OF UGN-101 FOR UPPER TRACT UROTHELIAL CANCER
15. MP31-14 PREDICTORS OF CLINICALLY SIGNIFICANT PROSTATE CANCER AMONGST AFRICAN AMERICAN MEN WITH PI-RADS 3 INDEX LESION UNDERGOING MRI-TARGETED BIOPSY
16. MP70-04 FACTORS ASSOCIATED WITH PROLONGED TIME INTERVAL BETWEEN MRI AND MRI-FUSION TARGETED PROSTATE BIOPSY: A DISPARITY IN CANCER CARE
17. PD48-01 EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL
18. MP02-16 CAN GENITOURINARY CANCER SURVIVORS UNDERSTAND QUALITY OF LIFE (QoL) QUESTIONNAIRES? ASSESSING THE READABILITY OF COMMONLY USED UROLOGIC ONCOLOGY QoL INSTRUMENTS
19. MP35-15 EFFICACY OF INPATIENT, EVIDENCE-BASED TOBACCO USE TREATMENT OF PATIENTS WITH BLADDER CANCER AFTER RADICAL CYSTECTOMY
20. PD29-03 ASSOCIATION OF SMOKING WITH CONCURRENT AND LONG-TERM HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES IN PROSTATE CANCER SURVIVORS
21. Systematic review of smoking relapse rates among cancer survivors who quit at the time of cancer diagnosis
22. Testis Cancer Care in North Carolina: Implications for Real-World Evidence and Cancer Surveillance
23. Development and Pilot Evaluation of a Decision Aid for Small Kidney Masses
24. Perceptions of e-cigarette harm among cancer survivors: Findings from a nationally representative survey
25. National assessment of recommendations from healthcare providers for smoking cessation among adults with cancer
26. Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials
27. Patterns and associations of smoking and electronic cigarette use among survivors of tobacco related and non-tobacco related cancers: A nationally representative cross-sectional analysis
28. Controversies in Prostate Cancer Diagnosis and Management
29. Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study
30. Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors1
31. Detection of Testicular Metastasis from Renal Cell Carcinoma on PSMA-PET Scan
32. EVALUATION OF GENOMIC AND TRANSCRIPTOMIC ALTERATIONS AND INTRATUMORAL HETEROGENEITY IN SMALL RENAL MASSES UPSTAGED TO PATHOLOGIC T3A CLEAR CELL RENAL CELL CARCINOMA
33. EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC FOR PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER: 36-MONTH FOLLOW-UP FROM A PHASE 3 TRIAL
34. TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NONMUSCLE-INVASIVE BLADDER CANCER WITH UGN-102 ± TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) COMPARED TO TURBT MONOTHERAPY: THE PHASE 3 ATLAS TRIAL
35. Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort
36. Carcinogen Biomarkers in the Urine of Electronic Cigarette Users and Implications for the Development of Bladder Cancer: A Systematic Review
37. First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors
38. Overall Survival of Biopsy-confirmed T1B and T2A Kidney Cancers Managed With Observation: Prognostic Value of Tumor Histology
39. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
40. The association between patient experience and healthcare outcomes using SEER-CAHPS patient experience and outcomes among cancer survivors
41. Bladder cancer patient and provider perspectives on smoking cessation
42. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer
43. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma
44. Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC)
45. ACR Appropriateness Criteria® Radiologic Management of Urinary Tract Obstruction
46. Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report
47. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer
48. Lack of Health Insurance Associated With Lower Probability of Head Computed Tomography Among United States Traumatic Brain Injury Patients
49. Impact of Trauma Center Designation and Interfacility Transfer on Renal Trauma Outcomes: Evidence for Universal Management
50. Outcomes and peri-operative complications of robotic pyelolithotomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.